Lihui Ouyang
Biographic Data
| ID | 10021858 |
|---|---|
| NAME | Lihui Ouyang |
| GIVEN NAMES | Lihui |
| FAMILY NAME | Ouyang |
| SIGNATURE | OUYANG L |
| AFFILIATIONS | The First Hospital of Changsha |
| VERIFIED | No |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2022 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer
Objectives: Rezvilutamide, an androgen-receptor inhibitor, has been approved by the Chinese National Medical Products Administration as a first-line treatment for high-volume metastatic hormone-sensitive prostate cancer (mHSPC). This study aims to assess the cost-effectiveness of rezvilutamide plus androgen-deprivation therapy (ADT) compared to bicalutamide plus ADT for the first-line treatment of high-volume mHSPC in China. Methods: A Markov mod…
Attitude and Needs Toward MTM Applications of Chronic Disease in China
Objective Chronic diseases are characterized by high incidence, long-term medication, and complex types of medication. There are also many corresponding medication therapy management (MTM) applications on the market, such as iCarea, and Medisafe. However, the existing research mainly focuses on how to choose high-quality MTM applications, and few researchers consider the expectations of MTM applications from potential users. The aims of this stud…
No prominent works on this page.
Attitude and Needs Toward MTM Applications of Chronic Disease in China
Objective Chronic diseases are characterized by high incidence, long-term medication, and complex types of medication. There are also many corresponding medication therapy management (MTM) applications on the market, such as iCarea, and Medisafe. However, the existing research mainly focuses on how to choose high-quality MTM applications, and few researchers consider the expectations of MTM applications from potential users. The aims of this stud…
Cost-effectiveness analysis of rezvilutamide versus bicalutamide and androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer
Objectives: Rezvilutamide, an androgen-receptor inhibitor, has been approved by the Chinese National Medical Products Administration as a first-line treatment for high-volume metastatic hormone-sensitive prostate cancer (mHSPC). This study aims to assess the cost-effectiveness of rezvilutamide plus androgen-deprivation therapy (ADT) compared to bicalutamide plus ADT for the first-line treatment of high-volume mHSPC in China. Methods: A Markov mod…
Internal Medicine (2 works) · Medicine (2 works) · Androgen (1 works) · Androgen deprivation therapy (1 works) · Androgen receptor (1 works) · Bicalutamide (1 works) · Breast cancer (1 works) · Cancer (1 works) · China (1 works) · Chronic disease (1 works)